HIV vaccine trial discontinued since the vaccine failed to prevent infections from human immunodeficiency virus, the virus that causes AIDS.
The National Institute of Allergy and Infectious Diseases or NIAID, which sponsored the trial. They announced on Monday that the study taking place in South Africa stops. After an independent data and safety monitoring board found that the vaccine is ineffective in preventing HIV.
Furthermore, Dr. Anthony Fauci, director of the NIAID, said in a written statement.
An HIV vaccine is essential to end the global pandemic, and we hoped this vaccine candidate would work. Regrettably, it does not.
Research continues on other approaches to a safe and effective HIV vaccine, which I still believe can be achieved.
Coronavirus: Spreading Across the Globe and What You Need to Know
Diet Plans: Everything you need to know about ‘Keto Diet,’ Is it safe?
HIV vaccine trial fails
In a separate news release, the Global HIV Vaccine Enterprise announced “deep disappointment” that the vaccine study had been stopped. Above all the enterprise is an alliance of funders and stakeholders form to boost the search for a vaccine.
Furthermore, Linda-Gail Bekker, immediate past president of the International AIDS Society and chair of the Enterprise Advisory Group, said in that separate announcement.
Whilst this is a significant setback for the field, we need to continue the quest for a preventive vaccine. The rates of HIV infection, which continue unabated in this region, should spur greater urgency, global attention and investment to the quest.
Meanwhile, the vaccine trial, named HVTN 702 or Uhambo, began in 2016 and enrolled 5,407 HIV-negative volunteers at 14 sites across South Africa, according to NIAID. Those volunteers were sexually active men and women ages 18 to 35 who were randomly assigned to receive either the vaccine or placebo injections.